Institutional Ownership

4D MOLECULAR THERAPEUTICS IN (FDMT) Institutional Ownership & Top Holders

The most recent SEC Form 13F filings (Q1 2026) show 3 hedge funds and institutional investors holding a combined 1.9M shares of 4D MOLECULAR THERAPEUTICS IN (FDMT), valued at $17.8M. The median portfolio weight is 0.7%.

The latest institutional ownership changes for FDMT show net buying, with the combined position up by 958K shares (100.7%) from the previous quarter.

Among 13F filers, the funds with the highest portfolio allocation to FDMT are Trails Edge Capital Partners (2.9% of its 13F portfolio), Exome Asset Management (0.7%), and RTW Investments (0.0%). In Q1 2026, Trails Edge Capital Partners made the largest position increase (+2.9%), while Baker Bros. Advisors made the largest reduction (-0.0%).

Top 3 Institutional Holders in 4D MOLECULAR THERAPEUTICS IN (FDMT), Ranked by Portfolio Weight

Based on the latest SEC Form 13F filings (Q1 2026).

# Fund Shares Market Value Portfolio Weight
1 Trails Edge Capital Partners 1,302,917 $12.1M 2.9%
2 Exome Asset Management 130,564 $1.2M 0.7%
3 RTW Investments 475,737 $4.4M 0.0%
Latest
  • 3
    Institutional investors
  • 1,909,218
    Shares held (disclosed)
  • $17.8M
    13F market value
  • 0.7%
    Median portfolio weight

Ownership History

Quarter-by-quarter share count, market value, and portfolio conviction weight (up to 5 of the heaviest weight-by-portfolio funds) of FDMT. Sourced from 13F filings; reflects long equity positions only.

Quarter-over-Quarter ActivityQ1 2026

The biggest weight-increase and weight-decrease changes among funds that hold FDMT. Deltas compare the selected filing to the previous reporting quarter.

Top buyers

Top sellers

Ownership Statistics

Funds holding
3
Median weight
0.7%
Largest holder
Trails Edge Capital Partners · 2.9%
Smallest holder
RTW Investments · 0.0%
Shares held
1,909,218 (+957,744)

All Institutional HoldersSortable · searchable

All institutional investors (Max 50) holding FDMT in the selected quarter. Click a fund name to drill into its full 13F portfolio.

3 of 3 institutional investors
1Trails Edge Capital Partners1,302,917$12.1M2.9%
2Exome Asset Management130,564$1.2M0.7%
3RTW Investments475,737$4.4M0.0%

Institutional Investor Count Over Time

Number of institutional investors disclosing a long position in 4D MOLECULAR THERAPEUTICS IN (FDMT) each reporting quarter. Sourced from SEC Form 13F-HR filings.

Methodology & FAQ

Methodology: How We Track FDMT Institutional Holdings

Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).

  • Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
  • What is Included (Data Scope): We capture long positions in Section 13(f) securities for 4D MOLECULAR THERAPEUTICS IN (FDMT). By SEC regulation, 13F filings do not require the disclosure of short positions, non-U.S. holdings, or OTC derivatives. Listed options are excluded from portfolio weight calculations to ensure comparability across filers.
  • Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to FDMT on the specific reporting date.
  • How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
How do you measure hedge fund conviction and institutional concentration in FDMT?

We evaluate fund conviction by looking at portfolio weight rather than just absolute share count. By tracking how the largest holders —such as Trails Edge Capital Partners , Exome Asset Management , and RTW Investments as of Q1 2026 change their position sizing quarter-over-quarter, we help investors distinguish between deliberate position sizing changes and passive mark-to-market drift.

Does the FDMT ownership data include short interest or options?

SEC Form 13F mandates the disclosure of long positions in Section 13(f) securities, which includes equities and listed options (put and call contracts), but excludes short interest, swaps, and OTC derivatives by regulatory design. On this platform, listed options are excluded from portfolio weight calculations to ensure comparability across filers.

Are family offices and university endowments included in this FDMT data?

Yes. In addition to traditional hedge funds and large asset managers, any institutional entity exercising investment discretion over at least $100 million in Section 13(f) securities must file a Form 13F. This explicitly includes single-family offices and university endowments. If a qualifying family office or endowment holds FDMT stock, their allocation is systematically aggregated alongside traditional fund data.

When is the institutional ownership data updated, and is there a reporting lag?

Institutional investment managers are required to file their Form 13F within 45 days after the end of a calendar quarter (the standard “T+45” window). Our platform re-ingests new filings from the SEC EDGAR database on a nightly cycle, typically within 24–48 hours of publication, providing a point-in-time snapshot of reported consensus positioning for FDMT as of each filing date.